An Abbreviated History of Aldosterone Metabolism, Current and Future Challenges

Abstract

The initial isolation of adrenal steroids from large quantities of animal adrenals resulted in an amorphous fraction resistant to crystallization and identification and had potent effects on electrolyte transport. Aldosterone was eventually isolated and identified in the fraction and was soon shown to cause hypertension when in excess. The autonomous and excessive production of aldosterone, primary aldosteronism, is the most common cause of secondary hypertension. Aldosterone is metabolized in the liver and kidney, and its metabolites are conjugated with glucuronic acid for excretion. The most common liver metabolite is 3α,5β-tetrahydroaldosterone-3-glucuronide, while that of the kidney is aldosterone-18-oxo-glucuronide. In terms of their value, especially the aldosterone-18-oxo-glucuronide, is commonly used for the diagnosis of primary aldosteronism because they provide an integrated value of the total daily production of aldosterone. Conversion of aldosterone to 18-oxo-glucuronide is impeded by drugs, like some common non-steroidal anti-inflammatory drugs that compete for UDP-glucuronosyltransferase-2B7, the most important glucuronosyltransferase for aldosterone metabolism. Tetrahydroaldosterone is the most abundant metabolite and the most reliable for the diagnosis of primary aldosteronism, but it is not commonly measured.

Key words

GH Adrenal gland - Hormones - aldosterone - primary aldosteronism

Publikationsverlauf

Eingereicht: 16. Januar 2023
Eingereicht: 02. März 2023

Angenommen: 09. März 2023

Accepted Manuscript online:
14. März 2023

Artikel online veröffentlicht:
08. Mai 2023

• References

• 1 Miller WL, White PC. History of adrenal research: From ancient anatomy to contemporary molecular biology. Endocr Rev 2023; 44: 70-116
• 2 Addison T. Chronics suprarenal insufficiency, usually due to tuberculosis of suprarenal capsule. Lond Med. Gazette 1849; 43: 517-518
• 3 Yamashima T. Jokichi Takamine (1854-1922), the samurai chemist, and his work on adrenalin. J Med Biogr 2003; 11: 95-102
• 4 Swingle WW, Pfiffner JJ. The revival of comatose adrenalectomized cats with an extract of the suprarenal cortex. Science 1930; 72: 75-76
• 5 Hartman FA, Brownell KA. The hormone of the adrenal cortex. Science 1930; 72: 76
• 6 Reichstein T, Reich H. The chemistry of the steroids. Annu Rev Biochem 1946; 15: 155-192
• 7 Von Euw J, Reichstein T. About components of the adrenal cortex and related substances; Configuration of the cortico steroids. Helv Chim Acta 1947; 30: 205-217
• 8 Steiger M, Reichstein T. Desoxy-corticosterone (21-oxy-progesterone). Aus d-3-oxo-etiocholensäure. Helv Chim Acta 1937; 20: 1164
• 9 Thorn GW, Howard RP, Emerson K. Treatment of Addison’s disease with desoxy-corticosterone acetate, a synthetic adrenal cortical hormone (preliminary report). J Clin Invest 1939; 18: 449-467
• 10 Wintersteiner O, Pfiffner JJ. Chemical studies on the adrenal cortex III. Isolation of two new physiologically inactive compounds. J Biol Chem 1936; 127: 291-305
• 11 Conn JW, Louis LH, Fajans SS. The probability that compound F (17-hydroxycorticosterone) is the hormone produced by the normal human adrenal cortex. Science 1951; 113: 713-714
• 12 Fourman P, Bartter FC, Albright F. et al. Effects of 17-hydroxycorticosterone (“compound F”) in man. J Clin Invest 1950; 29: 1462-1473
• 13 Amelung D, Hubener HJ, Roka L. et al. Conversion of cortisone to compound F. J Clin Endocrinol Metab 1953; 13: 1125-1126
• 14 Tait SA, Tait JF, Coghlan JP. The discovery, isolation and identification of aldosterone: Reflections on emerging regulation and function. Mol Cell Endocrinol 2004; 217: 1-21
• 15 Dorfman RI, Potts AM, Feil ML. Studies on the bioassay of hormones; the use of radiosodium for the detection of small quantities of desoxycorticosterone. Endocrinology 1947; 41: 464-469
• 16 Simpson SA, Tait JF. A quantitative method for the bioassay of the effect of adrenal cortical steroids on mineral metabolism. Endocrinology 1952; 50: 150-161
• 17 Axelrad BJ, Cates JE, Johnson BB. et al. Bioassay of mineralocorticoids: Relationship of structure to physiological activity. Endocrinology 1954; 55: 568-574
• 18 Simpson SA, Tait JF, Bush IE. Secretion of a salt-retaining hormone by the mammalian adrenal cortex. Lancet 1952; 1: 226-232
• 19 Grundy HM, Simpson SA, Tait JF. Isolation of a highly active mineralocorticoid from beef adrenal extract. Nature 1952; 169: 795-796
• 20 Bush IE. Methods of paper chromatography of steroids applicable to the study of steroids in mammalian blood and tissues. Biochem J 1952; 50: 370-378
• 21 Tait JF, Tait SAS. A steroid memoir: A decade (or more) of electrocortin (aldosterone). Steroids 1988; 51: 213-250
• 22 Deming QB, Luetscher JA. Bioassay of desoxycorticosterone-like material in urine. P Soc Exp Biol Med 1950; 73: 171-175
• 23 Luetscher JA, Dowdy A, Harvey J. et al. Isolation of crystalline aldosterone from the urine of a child with the nephrotic syndrome. J Biol Chem 1955; 217: 505-512
• 24 Deming QB, Luetscher JA. Increased sodium-retaining corticoid excretion in edema, with some observations on the effects of cortisone in nephrosis. J Clin Invest 1950; 29: 808
• 25 Luetscher JA, Axelrad BJ. Increased aldosterone output during sodium deprivation in normal men. Proc Soc Exp Biol Med 1954; 87: 650-653
• 26 Simpson SA, Tait JF, Wettstein A. et al. Isolierung eines neuen kristallisierten hormons aus nebennieren mit besonders hoher wirksamkeit auf den mineralostoffwechsel. Experientia 1953; 9: 333-333
• 27 Simpson SA, Tait JF, Wettstein A. et al. Konstitution des aldosterons, des neuen mineralocorticoids. Experientia 1953; 10: 132-133
• 28 Tait SA, Tait JF. The correspondence of S.A.S. Simpson and J.F. Tait with T. Reichstein during their collaborative work on the isolation and elucidation of the structure of electrocortin (later aldosterone). Steroids 1998; 63: 440-453
• 29 Singh N, Taibon J, Pongratz S. et al. Absolute content determination by quantitative NMR (qNMR) spectroscopy: A curious case of aldosterone. RSC Adv 2021; 11: 23627-23630
• 30 Duax WL, Hauptman H. The crystal structure and molecular conformation of aldosterone. J Am Chem Soc 1972; 94: 54675471
• 31 Genard P, Palem-Vliers M, Denoel J. et al. Molecular configuration and conformation of aldosterone, 18-hydroxy-11-deoxycorticosterone and a new urinary 18-hydroxy-steroid--an N.M.R. study. J Steroid Biochem 1975; 6: 201-210
• 32 Schmidlin J, Anner G, Billeter JR. et al. Synthesis in aldosterone-series. I. Total synthesis of racemic aldosterone. Experientia 1955; 11: 365-368
• 33 Barton DHR, Basu NK, Day MJ. et al. Improved synthesis of aldosterone. J Chem Soc 1975; Perkins Trans I 2243-2251
• 34 Barton DHR, Beaton JM. A synthesis of aldosterone acetate. J Am Chem Soc 1961; 83: 4083-4089
• 35 Giroud CJP, Stachenko J, Venning EH. Secretion of aldosterone by the zona glomerulosa of rat adrenal glands incubated in vitro. Proc Soc Exp Biol Med 1956; 92: 154-158
• 36 Spat A, Hunyady L. Control of aldosterone secretion: A model for convergence in cellular signaling pathways. Physiol Rev 2004; 84: 489-539
• 37 Hattangady NG, Olala LO, Bollag WB. et al. Acute and chronic regulation of aldosterone production. Mol Cell Endocrinol 2012; 350: 151-162
• 38 Ayres PJ, Pearlman WH, Tait JF. et al. The biosynthetic preparation of [16-3H]aldosterone and [16-3H] corticosterone. Biochem J 1958; 70: 230-236
• 39 Tait JF. Review: The use of isotopic steroids for the measurement of production rates in vivo. J Clin Endocrinol Metab 1963; 23: 1285-1297
• 40 Ulick S, Laragh JH, Lieberman S. The isolation of urinary metabolite of aldosterone and its use to measure the rate of secretion of aldosterone by the adrenal cortex of man. Trans Ass Am. Phy 1958; 71: 225-235
• 41 Flood C, Layne DS, Ramcharan S. et al. An investigation of the urinary metabolites and secretion rates of aldosterone and cortisol in man and a description of methods for their measurement. Acta Endocrinol (Copenh) 1961; 36: 237-264
• 42 Tait JF, Tait SA, Little B. et al. The disappearance of 7-H-3-d-aldosterone in the plasma of normal subjects. J Clin Invest 1961; 40: 72-80
• 43 Tait JF, Bougas J, Little B. et al. Splanchnic extraction and clearance of aldosterone in subjetes with minimal and marked cardiac dysfunction. J Clin Endocrinol Metab 1965; 25: 219-228
• 44 Ulick S, Lieberman S. Evidence for the occurence of a metabolite of aldosterone in urine. J Am Chem Soc 1957; 79: 6567-6568
• 45 Ulick S, Laragh JH, Lieberman S. The isolation of a urinary metabolite of aldosterone and its use to measure the rate of secretion of aldosterone by the adrenal cortex of man. Trans Assoc Am Physicians 1958; 71: 225-235
• 46 Ulick S, Ramirez LC. Isolation and synthesis of the major metabolites of aldosterone and 18-hydroxycorticosterone. Meth Enzy 1975; 36: 503-512
• 47 Kelly WG, Bandi L, Lieberman S. Isolation and characterization of human urinary metabolites of aldosterone. V. Dihydroaldosterone and 21-deoxytetrahydroaldosterone. Biochemistry 1963; 2: 1249-1254
• 48 Kelly WG, Bandi L, Lieberman S. Isolation and characterization of human urinary metabolites of aldosterone. Iv. The synthesis and stereochemistry of two bicyclic acetal metabolites. Biochemistry 1963; 2: 1243-1249
• 49 Kelly WG, Bandi L, Shoolery JN. et al. Isolation and characterization of aldosterone metabolites from human urine; two metabolites bearing a bicyclic acetal structure. Biochemistry 1962; 1: 172-181
• 50 Lewicka S, Vecsei P, Bige K. et al. Urinary excretion of aldosterone metabolite Kelly-M1 in patients with adrenal dysfunction. J Steroid Biochem 1988; 29: 333-339
• 51 Winter J, Shackleton CH, O’Rourke S. et al. Bacterial formation of aldosterone metabolites. J Steroid Biochem 1984; 21: 563-569
• 52 Cozza EN, Lantos CP, Burton G. A highly lipophilic form of aldosterone. Isolation and characterization of an aldosterone dimer. J Steroid Biochem 1985; 23: 511-516
• 53 Harnik M, Kashman Y, Cojocaru M. et al. 18,21-Anhydroaldosterone and derivatives. Steroids 1989; 54: 11-19
• 54 Latif SA, Morris DJ, Wei L. et al. 18-substituted steroids--Part 17. 2 Alpha-hydroxylated liver metabolites of aldosterone identified by high-field [1H]NMR spectroscopy. J Steroid Biochem 1989; 33: 1119-1125
• 55 Kirk DN, Burke PJ, Toms HC. et al. 18-Substituted steroids. Part 15. 6 Beta-hydroxylation of aldosterone by liver. Steroids 1989; 54: 169-184
• 56 Morris DJ. The metabolism and mechanism of action of aldosterone. Endocr Rev 1981; 2: 234-247
• 57 Kenyon CJ, Brem AS, McDermott MJ. et al. Antinatriuretic and kaliuretic activities of the reduced derivatives of aldosterone. Endocrinology 1983; 112: 1852-1856
• 58 Gomez-Sanchez CE, Smith JS, Ferris MW. et al. Renal receptor binding activity of reduced metabolites of aldosterone: Evidence for a mineralocorticoid effect outside of the classic aldosterone receptor system. Endocrinology 1984; 115: 712-715
• 59 Gorsline J, Latif SA, Morris DJ. Changes in 5 alpha- and 5 beta-reductase pathways of aldosterone metabolism by dietary sodium. Am J Hypertens 1988; 1: 272-275
• 60 Morris DJ, Kenyon CJ, Latif SA. et al. The possible biological role of aldosterone metabolites. Hypertension 1983; 5: I35-I40
• 61 Grose JH, Nowaczynski W, Kuchel O. et al. Isolation of aldosterone urinary metabolites, glucuronides and sulfate. J Steroid Biochem 1973; 4: 551-566
• 62 Jowett TP, Slater JD. Aldosterone 21-sulphate in man. J Steroid Biochem 1983; 18: 471-479
• 63 Luetscher JA, Axelrad BJ. Sodium-retaining corticoid in the urine of normal children and adults and of patients with hypoadrenalism or hypopituitarism. J Clin Endocrinol Metab 1954; 14: 1086-1089
• 64 Axelrad BJ, Cates JE, Johnson BB. et al. Aldosterone in urine of normal man and of patients with oedema; its increased recovery after hydrolysis with acid and with beta-glucuronidase. Br Med J 1955; 1: 196-199
• 65 Pasqualini JR, Uhrich F, Jayle MF. Contribution to the study of the structure of the aldosterone-conjugate isolated from human urine. Biochim Biophys Acta 1965; 104: 515-523
• 66 Underwood RH, Tait JF. Purification, partial characterization and metabolism of an acid labile conjugate of aldosterone. J Clin Endocrinol Metab 1964; 24: 1110-1124
• 67 Luetscher JA, Camargo CA, Cohn AP. et al Observations on metabolism of aldosterone in man. Ann Intern Med 1963; 59: 1-7
• 68 Underwood RH, Flood CA, Tait SA. et al. A comparison of methods for the acid hydrolysis of a urinary conjugate of aldosterone. J Clin Endocrinol Metab 1961; 21: 1092-1098
• 69 Yin Y, Yu S, Qiu L. et al. Establishment of a rapid and simple liquid chromatography tandem mass spectrometry method for measuring aldosterone in urine. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1113: 84-90
• 70 Schirpenbach C, Seiler L, Maser-Gluth C. et al. Confirmatory testing in normokalaemic primary aldosteronism: The value of the saline infusion test and urinary aldosterone metabolites. Eur J Endocrinol 2006; 154: 865-873
• 71 Vecsei P, Abdelhamid S, Mittelstadt GV. et al. Aldosterone metabolites and possible aldosterone precursors in hypertension. J Steroid Biochem 1983; 19: 345-351
• 72 Tait JF, Little B. The metabolism of orally and intravenously administered labeled aldosterone in pregnant subjects. J Clin Invest 1969; 47: 2423-2429
• 73 Funder JW, Carey RM, Mantero F. et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101: 1889-1916
• 74 Brown JM, Siddiqui M, Calhoun DA. et al. The unrecognized prevalence of primary aldosteronism: A cross-sectional study. Ann Intern Med 2020; 173: 10-20
• 75 Ceral J, Malirova E, Ballon M. et al. The role of urinary aldosterone for the diagnosis of primary aldosteronism. Horm Metab Res 2014; 46: 663-667
• 76 Young WF. Primary aldosteronism: Renaissance of a syndrome. Clin Endocrinol (Oxf) 2007; 66: 607-618
• 77 Bravo EL. Primary aldosteronism: New approaches to diagnosis and management. Cleve Clin J Med 1993; 60: 379-386
• 78 Conn JW, Knopf RF, Nesbit RM. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159-172
• 79 Knights KM, Winner LK, Elliot DJ. et al. Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: Inhibition by NSAIDs. Br J Clin Pharmacol 2009; 68: 402-412
• 80 Girard C, Barbier O, Turgeon D. et al. Isolation and characterization of the monkey UGT2B30 gene that encodes a uridine diphosphate-glucuronosyltransferase enzyme active on mineralocorticoid, glucocorticoid, androgen and oestrogen hormones. Biochem J 2002; 365: 213-222
• 81 Girard C, Barbier O, Veilleux G. et al. Human uridine diphosphate-glucuronosyltransferase UGT2B7 conjugates mineralocorticoid and glucocorticoid metabolites. Endocrinology 2003; 144: 2659-2668
• 82 Knights KM, Mangoni AA, Miners JO. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: Is aldosterone the silent partner in crime?. Br J Clin Pharmacol 2006; 61: 738-740
• 83 Gaganis P, Miners JO, Brennan JS. et al Human renal cortical and medullary UDP-glucuronosyltransferases (UGTs): Immunohistochemical localization of UGT2B7 and UGT1A enzymes and kinetic characterization of S-naproxen glucuronidation. J Pharmacol Exp Ther 2007; 323: 422-430
• 84 Bello-Reuss E, Ernest S, Holland OB. et al. Role of multidrug resistance P-glycoprotein in the secretion of aldosterone by human adrenal NCI-H295 cells. Am J Physiol - Cell Physiol 2000; 278: 1256-1265
• 85 Zolk O, Jacobi J, Pahl A. et al. MDR1 genotype-dependent regulation of the aldosterone system in humans. Pharmacogenet Genomics 2007; 17: 137-144
• 86 Marques P, Courand PY, Gouin-Thibault I. et al. P-glycoprotein influences urinary excretion of aldosterone in healthy individuals. J Hypertens 2019; 37: 2225-2231
• 87 Griffing GT, Wilson TE, Melby JC. Altered fractional tetrahydroaldosterone excretion during pharmacological blockade and activation of the renin-aldosterone system. J Clin Endocrinol Metab 1982; 55: 1217-1221
• 88 Abdelhamid S, Blomer R, Hommel G. et al. Urinary tetrahydroaldosterone as a screening method for primary aldosteronism: A comparative study. Am J Hypertens 2003; 16: 522-530
• 89 Abdelhamid S, Vecsei P, Haack D. et al. Dissociation in the excretion of different aldosterone metabolites and unmetabolized (‘free’) aldosterone in hypertension. Clin Sci (Lond) 1979; 57: 409-414
• 90 Gomez-Sanchez CE, Holland OB. Urinary tetrahydroaldosterone and aldosterone-18-glucuronide excretion in white and black normal subjects and hypertensive patients. J Clin Endocrinol Metab 1981; 52: 214-219
• 91 Holland OB, Risk M, Brown H. et al. High-performance liquid chromatography in the radioimmunoassay of urinary tetrahydroaldosterone. J Chromatogr 1987; 385: 393-396
• 92 Ishida J, Sonezaki S, Yamaguchi M. et al. High-performance liquid chromatographic determination of 3 alpha,5 beta-tetrahydroaldosterone in human urine with chemiluminescence detection. Analyst 1992; 117: 1719-1724
• 93 Pratt JH, Holbrook MM, Dale SL. et al. The measurement of urinary tetrahydroaldosterone by radioimmunoassay. J Steroid Biochem 1977; 8: 677-681
• 94 Camargo CA, Dowdy AJ, Hancock EW. et al. Decreased plasma clearance and hepatic extraction of aldosterone in patients with heart failure. J Clin Invest 1965; 44: 356-365
• 95 Cheville RA, Luetscher JA, Hancock EW. et al. Distribution, conjugation, and excretion of labeled aldosterone in congestive heart failure and in controls with normal circulation: Development and testing of a model with an analog computer. J Clin Invest 1966; 45: 1302-1316
• 96 Griffing GT, Wilson TE, Melby JC. Alterations in aldosterone secretion and metabolism in low renin hypertension. J Clin Endocrinol Metab 1990; 71: 1454-1460
• 97 Alvarez MN, Carpenter PC, Mattox VR. Isolation of tetrahydroaldosterone 3beta-glucosiduronic acid from urine. J Steroid Biochem 1976; 7: 661-664
• 98 Mattox VR, Nelson AN. Determination of urinary tetrahydroaldosterone glucosiduronic acid by radioimmunoassay. J Steroid Biochem 1981; 14: 243-249
• 99 Deck KA, Champion PK, Conn JW. Urinary free aldosterone in healthy people and in patients with primary aldosteronism. J Clin Endocrinol Metab 1973; 36: 756-760
• 100 Freeman MW, Halvorsen YD, Marshall W. et al. Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 2023; 388: 395-405